Schrödinger (NASDAQ:SDGR) Given New $32.00 Price Target at KeyCorp

Schrödinger (NASDAQ:SDGR) had its target price increased by analysts at KeyCorp from $30.00 to $32.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has an “overweight” rating on the stock. KeyCorp’s target price would indicate a potential upside of 25.05% from the stock’s previous close.

Separately, Piper Sandler dropped their price objective on Schrödinger from $50.00 to $45.00 and set an “overweight” rating for the company in a report on Thursday, February 27th. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $33.00.

Schrödinger Stock Down 3.6 %

Shares of NASDAQ:SDGR opened at $25.59 on Wednesday. The business has a 50 day moving average price of $21.98 and a 200 day moving average price of $20.84. The company has a market cap of $1.87 billion, a price-to-earnings ratio of -10.94 and a beta of 1.77. Schrödinger has a twelve month low of $16.60 and a twelve month high of $28.47.

Schrödinger (NASDAQ:SDGR) last posted its earnings results on Wednesday, February 26th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.20). Schrödinger had a negative net margin of 91.84% and a negative return on equity of 35.77%. The business had revenue of $88.32 million during the quarter, compared to the consensus estimate of $83.20 million. Analysts anticipate that Schrödinger will post -2.37 EPS for the current year.

Insider Transactions at Schrödinger

In other news, insider Karen Akinsanya sold 16,723 shares of the company’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $25.09, for a total value of $419,580.07. Following the sale, the insider now directly owns 15,625 shares of the company’s stock, valued at approximately $392,031.25. This represents a 51.70 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Geoffrey Craig Porges sold 5,491 shares of the company’s stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $21.76, for a total transaction of $119,484.16. Following the sale, the chief financial officer now directly owns 27,544 shares in the company, valued at $599,357.44. This trade represents a 16.62 % decrease in their position. The disclosure for this sale can be found here. 8.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Schrödinger

A number of institutional investors and hedge funds have recently modified their holdings of the business. Point72 Hong Kong Ltd acquired a new position in shares of Schrödinger during the 4th quarter valued at $27,000. Paradigm Asset Management Co. LLC acquired a new position in shares of Schrödinger during the fourth quarter valued at about $50,000. GAMMA Investing LLC boosted its position in shares of Schrödinger by 87.5% during the 4th quarter. GAMMA Investing LLC now owns 2,796 shares of the company’s stock worth $54,000 after purchasing an additional 1,305 shares in the last quarter. KBC Group NV grew its stake in shares of Schrödinger by 73.9% in the 4th quarter. KBC Group NV now owns 4,361 shares of the company’s stock valued at $84,000 after buying an additional 1,853 shares during the period. Finally, XTX Topco Ltd bought a new stake in Schrödinger in the 4th quarter valued at about $199,000. 79.05% of the stock is currently owned by institutional investors.

About Schrödinger

Schrödinger, Inc, together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries.